50398-72-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloromethyl-4-methyl-thiazole is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and medications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-chloromethyl-4-methyl-thiazole serves as an intermediate in the production of agrochemicals, aiding in the creation of substances that protect crops and enhance agricultural productivity.
Used in Dye Industry:
2-CHLOROMETHYL-4-METHYL-THIAZOLE is utilized as an intermediate in the synthesis of dyes, playing a role in the development of colorants for various applications, including textiles and other industries.
Used in Organic Synthesis:
2-Chloromethyl-4-methyl-thiazole is used as a reagent in organic synthesis for the preparation of a range of compounds, showcasing its versatility in chemical reactions and product development.
Used in Disinfectants and Antiseptics:
Leveraging its antimicrobial properties, 2-chloromethyl-4-methyl-thiazole is used in the formulation of disinfectants and antiseptics, contributing to the prevention of infections and maintaining hygiene in various settings.

InChI:InChI=1/C5H6ClNS/c1-4-3-8-5(2-6)7-4/h3H,2H2,1H3

Upstream product

• 13750-63-5 (4-methylthiazol-2-yl)-methanol 
• 13750-68-0 4-methyl-thiazole-2-carbaldehyde 

Downstream Products

• 19785-39-8 (4-methylthiazol-2-yl)acetonitrile 

Relevant academic research and scientific papers

IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS

Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.

HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS

Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.

FUSED PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON FMS KINASES

Disclosed are a fused pyrimidine derivative of formula (I), and a pharmaceutically acceptable salt, stereoisomer, hydrate and solvate thereof, which have an excellent inhibitory activity on FMS kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating diseases caused by abnormal activation of FMS kinases such as immunologic diseases, metabolic diseases, inflammatory diseases, cancers and tumors.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

ANTIMICROBIAL AGENTS

The invention provides compounds of formual (I): wherein R1-R7 and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.

FAAH INHIBITORS

The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the com

Diastereoselective synthesis of 2-oxiranyl and 2-aziridinyl thiazoles

2-Chloroalkylthiazolyllithiums, prepared by deprotonating the 2-chloroalkylthiazoles with n-BuLi at -78°C in THF, add to ketones or imines affording in 'one-pot' oxiranes and aziridines in a Z stereoselective manner.

PHARMACOLOGICALLY ACTIVE GUANIDINE COMPOUNDS

The compounds are substituted thioalkyl-, aminoalkyl-and oxyalkyl-guanidines which are inhibitors of histamine activity.

PHARMACOLOGICALLY ACTIVE THIOUREA AND UREA COMPOUNDS

The compounds are substituted thioalkyl-, aminoalkyl-and oxyalkyl-thioureas and ureas which are inhibitors of histamine activity.